The cost-effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III. [electronic resource]
Producer: 20100917Description: 1100-5 p. digitalISSN:- 1524-4733
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antihypertensive Agents -- economics
- Bosentan
- Child
- Confidence Intervals
- Connective Tissue Diseases -- complications
- Cost-Benefit Analysis
- Disease Progression
- Epoprostenol -- economics
- Female
- Health Care Costs
- Health Expenditures
- Humans
- Hypertension, Pulmonary -- complications
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Models, Economic
- Palliative Care -- economics
- Quality of Life
- Quality-Adjusted Life Years
- Sulfonamides -- economics
- United Kingdom
- World Health Organization
- Young Adult
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.